MGMT and glioblastoma: Further stratification by MGMT status (unmethylated vs methylated), radiation dose (60 Gy in 30 fractions vs 40 Gy in 15 fractions), and age (<64 years vs ≥64 years) revealed significant difference in PFS of MGMT unmethylated patients with 13.1 months in the mol-GBM group vs 7.8 months in h-GBM (p=0.005), and in patients aged ≥64 years with 18.8 months and 8.9 months, respectively (p=0.04).